U lcerative colitis (UC) is a chronic inflammatory disease affecting the colon, characterized by a continuous mucosal inflammation starting at the rectum and with a variable proximal extent in the colon. [1] [2] [3] [4] [5] The course of the disease is characterized by periods of exacerbation of disease activity alternating with periods of remission. 5, 6 Clinical and endoscopic remissions are the currently accepted therapeutic targets in UC. Nevertheless, previous reports observed discrepancies between clinical and endoscopic findings. 4, 7 Clinical remission encompasses resolution of clinical symptoms, namely normalization of stool frequency (#3/d) and cessation of rectal bleeding. 3, 7 The Mayo endoscopic subscore (MSe) is the score system most widely used in the evaluation of endoscopic disease activity in UC. 8 Although an MSe of 0 is the optimal target, there is insufficient information to recommend it for all patients and an MSe of 1 should be a minimum target to achieve mucosal healing. 7 Patients who achieved mucosal healing had better long-term outcomes, including higher rates of sustained clinical remission, corticosteroid-free clinical remission, reduced rates of disease relapse, decreased risk of dysplasia and colorectal cancer, hospitalization, and colectomy. [7] [8] [9] [10] [11] [12] [13] Histological healing is currently not a target in UC because of limited evidence that it can provide additional prognostic and clinical utility beyond the previously mentioned therapeutic targets in UC. 2, 7 Nevertheless, accumulating evidence indicates that it is associated with improved clinical outcomes in UC and could represent the ultimate therapeutic goal in UC, as up to 40%-50% of patients with mucosal healing still have persistent histological inflammatory activity. 2, [6] [7] [8] This study aims to determine the impact of the definition of endoscopic remission (MSe 0-1) and histological activity in the recurrence of UC and the recurrence-free time.
METHODS
All patients with an established diagnosis of UC in clinical and endoscopic remissions who underwent colonoscopy with biopsies in our department between March 2010 and December 2013 were enrolled. Exclusion criteria were patients younger than 18 years, patients on corticosteroids that could potentially mask clinical signs and symptoms, absence of clinical or endoscopic remission at the time of the colonoscopy, and lack of biopsy specimens at the considered colonoscopy.
Clinical Activity Assessment
Partial Mayo score (MSp) was used to evaluate clinical disease activity, which encompasses stool frequency, rectal bleeding, and physician's global assessment. 8, 14 This score ranges from 0 to 9, and clinical remission was defined as an MSp #1. 8, 14 Information regarding clinical symptoms was retrospectively collected from the clinical files.
Endoscopic Mucosal Assessment
Colonoscopies were performed to evaluate endoscopic remission in patients in clinical remission on maintenance therapy, to evaluate the need for optimization of therapy to achieve the target goals in the treatment of UC (clinical and endoscopic remissions).
All colonoscopy reports were reviewed, and the information provided allowed the classification of endoscopic activity using the MSe. Endoscopic remission was defined as an MSe #1, with MSe ¼ 0 representing normal or inactive disease and MSe ¼ 1 corresponding to mild disease with erythema and decreased vascular pattern. 12, 15 Histological Assessment
In our department, biopsies are performed according to the European Crohn's and Colitis Organisation consensus with a minimum of 2 samples from at least 5 sites of the colon (including rectum) and the terminal ileum, collected to separate containers. 3 The validated Nancy score 2 was used to evaluate histological activity of biopsy specimens, and the worst grade obtained was included for each patient. This score is composed by 5 grades (Table 1) , and the authors define histological inactivity for grades 0 and 1 and histological activity for grades 2 to 4. 2, 16 The histological reports were reviewed and classified according to the Nancy score. The worst score obtained was considered if different classifications in the Nancy score were obtained from the different segments of the colon.
Outcomes
Patients were followed until the end of the study in October 2016 or until recurrence. The recurrence-free time was then evaluated, and recurrence was defined as MSp $2, therapy to induce remission, hospitalization, or colectomy. Predictive factors associated with recurrence and with time to recurrence were determined.
Statistical Analysis
Continuous data are presented using the mean and SD, whereas proportions and percentages were used to describe discrete variables. The x 2 test was used to compare proportions across 2 groups of discrete variables, whereas Student's t test was used to compare continuous data between 2 groups. Kaplan-Meier survival curves were used to estimate the time to recurrence. The log-rank test was used in the univariate analysis to compare the time to recurrence across 2 groups. Finally, coxproportional models were used in the multivariate analysis to evaluate variables found to influence time to recurrence in the univariate analysis. The results were considered statistically significant when the P value was , 0.05.
RESULTS
Between March 2010 and December 2013, 82 patients in clinical remission with no corticosteroids performed colonoscopy. Eleven patients were excluded because they had endoscopic activity (MSe ¼ 3, n ¼ 1 and MSe ¼ 2, n ¼ 9). In addition, 11 patients in clinical and endoscopic (MSe ¼ 1, n ¼ 1 and MSe ¼ 0, n ¼ 10) remissions were also excluded because no biopsies were taken during the abovementioned colonoscopy. Therefore, 60 Acute inflammatory cell infiltrate is defined by the presence of neutrophils in the lamina propria and/or epithelial cells. 2, 16 patients were included in our study; 58.3% (n ¼ 35) of those were women. By the time of the colonoscopy, the mean age of patients and duration of UC were 48.4 (614.2) and 5.2 (64.6) years, respectively. Regarding the extent of the disease according to the Montreal classification, 33.3% had extensive UC, 36.7% left-sided UC, and 30% ulcerative proctitis. The majority of patients was on aminosalicylates (88.3%). MSe ¼ 0 was observed in 53.3% (n ¼ 32) and MSe ¼ 1 in 46.7% (n ¼ 28), and histological inactivity occurred in 61.7% (n ¼ 37) ( Table 2) . Clinical recurrence occurred in 31.7% (n ¼ 19) of patients. All patients with recurrence presented an MSp $2 and needed to start therapy to induce remission (Table 3) . Moreover, 3 patients were hospitalized and 1 underwent colectomy ( Table 3 ). The cumulative risk of recurrence was 17.1%, 24.5%, 26.7%, and 40.1% at 12, 24, 36, and 48 months, respectively (Fig. 1) .
Regarding MSe, recurrence occurred in 46.4% (n ¼ 13) of patients with MSe ¼ 1 and 18.8% (n ¼ 6) of patients with MSe ¼ 0. Patients with histological activity (Nancy score 2-4) had a clinical recurrence in 52.2% (n ¼ 12) of the cases, and patients with histological inactivity (Nancy score 0-1) recurred in 18.9% (n ¼ 7) of the cases.
MSe ¼ 1 (P ¼ 0.02) and histological activity (P ¼ 0.007) were significantly associated with recurrence (Table 4) . No difference between the duration of remission and the relapse was found. The mean duration of remission in relapsing patients was 36.9 and 42.9 months in nonrelapsing patients (P ¼ 0.6). Moreover, neither age, sex, disease extension, nor the type of therapy was significantly associated with recurrence. Of these, only histological activity (P ¼ 0.03) was an independent predictive factor of recurrence.
Patients with MSe ¼ 1 (P ¼ 0.02) (Fig. 2) and with histological activity (P ¼ 0.01) (Fig. 3) had a significantly shorter recurrence-free time in the univariate analysis, mainly in the subgroup of patients with MSe ¼ 1 and histological activity (P ¼ 0.006) (Fig. 4) . Nevertheless, the recurrencefree time was neither significantly different between patients with MSe ¼ 1 with or without histological activity (P ¼ 0.053) nor between patients with MSe ¼ 0 with or without activity (P ¼ 0.8). The remaining variables (age, sex, disease extension, and type of therapy) were not significantly associated with the time to recurrence. In multivariate analysis, only histological activity (P ¼ 0.02) was an independent predictive factor of lower recurrence-free time.
DISCUSSION
In our study, patients with UC in clinical and endoscopic remissions experienced a global recurrence of 31.7%, reaching 40.1% in 48 months.
In univariate analysis, MSe ¼ 1 was significantly associated with recurrence (P ¼ 0.02) and earlier recurrence (P ¼ 0.02). The authors adopted MSe to classify endoscopic remission because it represents the classification adopted in most clinical trials. Nevertheless, only the Ulcerative Colitis Endoscopic Index of Severity received formal validation. 13 Endoscopic remission has been defined as an MSe # 1; however, current evidence defends that the optimal target should be restricted to grade 0. 13 Nevertheless, it remains controversial if a difference between an MSe of 0 and an MES of 1 has an impact in clinical outcomes. 17, 18 Some previous studies reported no differences in relapse between patients with MSe ¼ 0 and MSe ¼ 1. 17, 18 Conversely, other reports concluded that MSe ¼ 1 was significantly associated with higher clinical relapse rates, and thus, endoscopic remission should be reserved for MSe ¼ 0. 1, 5, 8, 9, [18] [19] [20] In the subgroup analysis of the ACT 1 and 2 trials, a significant difference in corticosteroid-free remission after 1 year of follow-up was achieved between patients with MSe ¼ 0 (73%) and patients with MSe ¼ 1 (47%) (P , 0.001). 21 Previous studies have shown discrepancies between endoscopic remission and histological remission, demonstrating that up to 40% of patients with clinical and endoscopic remissions still had histological activity. 4, 10, 17 Our study achieved similar findings, with 38.3% of patients with mucosal healing (MSe 0 or 1) still maintaining histological activity (Nancy score 2-4). The importance of this finding was issued in a recent meta-analysis which observed a reduction of 49% in the relative risk of a relapse when patients with histological healing were compared with those with mucosal healing but persistent histological activity. 10 In our study, only the presence of histological activity independently predicted recurrence and earlier recurrence in UC. Our findings are similar to previous studies, reporting that histological activity in UC was associated with clinical relapse. 6, 17, 22 Moreover, a previous study concluded that histological parameters, namely basal plasmacytosis on rectal biopsies specimens, independently predicted earlier recurrence in UC. 23 A recent meta-analysis concluded that histological activity provides clinically important prognostic information, beyond the one provided by clinical and endoscopic remissions, as histological remission predicted a significant 52% relative risk reduction in clinical relapse or exacerbation of UC as compared to the presence of histological activity. 10 Furthermore, histological remission predicted a significant 20% relative risk reduction in clinical relapse or disease exacerbation when compared with the currently used standards of clinical and endoscopic remissions. 10 Nowadays, a validated scale universally accepted for grading histological activity in UC is lacking, as well as a standardized and uniformly accepted definition for histological healing in UC. 2, 10 These aspects may turn more difficult the implementation of the histological healing as the ultimate therapeutic goal in UC. The presence of neutrophils in the epithelium or lamina propria seems to be a generally accepted marker of disease activity. 10 In Recurrence-free time according to the Nancy score. In Nancy score 0 to 1, 37, 34, 34, 26, 14, 7, and 4 patients without recurrence were followed at 0, 12, 24, 36, 48, 60, and 72 months, respectively. In Nancy Score 2 to 4, 23, 19, 17, 14, 9, 5, and 0 patients without recurrence at 0, 12, 24, 36, 48, 60, and 72 months were followed, respectively.
our study, we adopted the Nancy histological index because it is a validated score, with a very good intraobserver and interobserver reliability, as acknowledged by the authors who developed the score. 2 Moreover, it is a simple and practical score to use and is in line with current evidence that identifies the presence of neutrophils as a marker of histological activity. 2, 10 Because of the retrospective nature of our study, endoscopic and histological scores were determined by reviewing the reports, which is a limitation of our study. Nevertheless, the endoscopic and histological assessments in our article represent a real-life experience, and therefore, the results of our study may be more relevant in routine clinical practice. In summary, patients with UC in clinical and endoscopic remissions experienced a global recurrence of 31.7% (n ¼ 19), reaching 40.1% in 48 months. Only the presence of histological activity represents an independent predictive factor of recurrence and time to recurrence, indicating a potential role of histology to improve predictions for clinical outcome when added to endoscopic or clinical remission in UC.
